TNFRSF17 and Miyoshi myopathy: B-cell maturation antigen (BCMA), also known as TNFRSF17, has been the preferred antigen targeted by CAR T-cells directed against MM, as it is highly expressed in most MM malignancies and CAR T-Cell therapies directed against this surface antigen have elicited powerful antitumor responses in relapsed or refractory patients (5, 7–9).